索拉非尼联合标准化疗治疗高等位基因比值FLT3/ITD阳性儿童急性髓系白血病:儿童肿瘤协作组AAML1031方案报告
该研究在儿童高等位基因比值FLT3/ITD阳性急性髓系白血病中评估索拉非尼联合标准化疗及单药维持治疗的可行性与疗效。索拉非尼最大耐受剂量为200 mg/m2每日一次,药代动力学显示血浆浓度足以抑制磷酸化FLT3。校正移植和有利共存突变后,未接受索拉非尼者事件风险约高两倍。
要点
- 索拉非尼最大耐受剂量为200 mg/m2每日一次,剂量限制性毒性包括皮疹、手足综合征和发热。
- 药代动力学/血浆抑制活性数据显示实测血浆浓度足以抑制磷酸化FLT3。
- 校正移植和有利共存突变后,未接受索拉非尼者事件风险约高两倍。
核心结论
- 索拉非尼可安全加入常规急性髓系白血病化疗,并可能改善儿童高等位基因比值FLT3/ITD阳性急性髓系白血病的结局。
研究设计与样本
- 儿童肿瘤协作组AAML1031方案,患者分三个队列治疗,初始安全阶段确定从诱导2开始的索拉非尼最大耐受剂量,队列2和3在诱导期加入索拉非尼并作为单药维持治疗。
- 临床结局分析限于队列2/3的n=72例患者,与n=76例接受相同化疗但未用索拉非尼的高等位基因比值FLT3/ITD阳性急性髓系白血病患者比较。
- 在部分患者中测量了索拉非尼药代动力学和血浆抑制活性。
主要发现
- 索拉非尼最大耐受剂量为200 mg/m2每日一次;剂量限制性毒性包括皮疹(n=2;1例3级和1例2级)、2级手足综合征和3级发热。
- 药代动力学/血浆抑制活性数据显示实测血浆浓度足以抑制磷酸化FLT3。
- 接受索拉非尼的队列2和3患者结局优于对照,但接受索拉非尼者接受造血干细胞移植也比对照人群更频繁。
- 校正造血干细胞移植和有利共存突变的多变量分析证实索拉非尼获益:未接受索拉非尼的高等位基因比值FLT3/ITD阳性患者事件风险约高两倍(自研究入组无事件生存:风险比[HR] 2.37,95%CI 1.45至3.88,P<.001;自完全缓解无病生存:HR 2.28,95%CI 1.08至4.82,P=.032;自完全缓解复发风险:HR 3.03,95%CI 1.31至7.04,P=.010)。
关键数值与推荐
- 高等位基因比值定义为等位基因比值>0.4。
- 索拉非尼最大耐受剂量为200 mg/m2每日一次。
- 未接受索拉非尼者自研究入组无事件生存HR 2.37(95%CI 1.45至3.88,P<.001)。
- 未接受索拉非尼者自完全缓解无病生存HR 2.28(95%CI 1.08至4.82,P=.032)。
- 未接受索拉非尼者自完全缓解复发风险HR 3.03(95%CI 1.31至7.04,P=.010)。
临床怎么用
- 索拉非尼可安全加入常规急性髓系白血病化疗,并可能改善儿童高等位基因比值FLT3/ITD阳性急性髓系白血病的结局。
局限性
- 临床结局分析样本量有限(队列2/3 n=72,对照n=76)。
- 接受索拉非尼者接受造血干细胞移植比对照人群更频繁。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High allelic ratio (HAR) FLT3/ITD (AR > 0.4) mutations confer poor prognosis in pediatric acute myeloid leukemia (AML). COG AAML1031 studied the feasibility and efficacy of adding sorafenib, a multikinase tyrosine kinase inhibitor to standard chemotherapy and as single-agent maintenance therapy in this population. MATERIALS AND METHODS: Patients were treated in three cohorts. The initial safety phase defined the maximum tolerated dose of sorafenib starting in induction 2. Cohorts 2 and 3 added sorafenib in induction and as single-agent maintenance. Clinical outcome analysis was limited to n = 72 patients in cohorts 2/3 and compared with n = 76 HAR FLT3/ITD+ AML patients who received identical chemotherapy without sorafenib. Sorafenib pharmacokinetics and plasma inhibitory activity were measured in a subset of patients. RESULTS: The maximum tolerated dose of sorafenib was 200 mg/m2 once daily; dose-limiting toxicities included rash (n = 2; 1 grade 3 and 1 grade 2), grade 2 hand-foot syndrome, and grade 3 fever. Pharmacokinetics/plasma inhibitory activity data demonstrated that measured plasma concentrations were sufficient to inhibit phosphorylated FLT3. Although outcomes were superior with sorafenib in cohorts 2 and 3, patients treated with sorafenib also underwent hematopoietic stem-cell transplant more frequently than the comparator population. Multivariable analysis that accounted for both hematopoietic stem-cell transplant and favorable co-occurring mutations confirmed sorafenib's benefit. Specifically, risk of an event was approximately two-fold higher in HAR FLT3/ITD+ patients who did not receive sorafenib (event-free survival from study entry: hazard ratio [HR] 2.37, 95% CI, 1.45 to 3.88, P < .001, disease-free survival from complete remission: HR 2.28, 95% CI, 1.08 to 4.82, P = .032, relapse risk from complete remission: HR 3.03, 95% CI 1.31 to 7.04, P = .010). CONCLUSION: Sorafenib can be safely added to conventional AML chemotherapy and may improve outcomes in pediatric HAR FLT3/ITD+ AML.
引用
- Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. J Clin Oncol. 2022. PMID: 35349331. doi:10.1200/JCO.21.01612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。